Co-targeting TGF-β and PD-L1 sensitizes triple-negative breast cancer to experimental immunogenic cisplatin-eribulin chemotherapy doublet

In preclinical mouse models of triple-negative breast cancer (TNBC), we show that a combination of chemotherapy with cisplatin (CDDP) and eribulin (Eri) was additive from an immunological point of view and was accompanied by the induction of an intratumoral immune and inflammatory response favored b...

תיאור מלא

מידע ביבליוגרפי

Principais autores:	Laura Kalfeist, Fanny Ledys, Stacy Petit, Cyriane Poirrier, Samia Kada Mohammed, Loïck Galland, Valentin Derangère, Alis Ilie, David Rageot, Romain Aucagne, Pierre-Simon Bellaye, Caroline Truntzer, Marion Thibaudin, Mickaël Rialland, François Ghiringhelli, Emeric Limagne, Sylvain Ladoire
פורמט:	Artigo
שפה:	Inglês
יצא לאור:	American Society for Clinical Investigation 2025-07-01
סדרה:	The Journal of Clinical Investigation
נושאים:	Immunology Oncology
גישה מקוונת:	https://doi.org/10.1172/JCI184422
תגים:	הוספת תג אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!